Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R King

Showing results (11-20 of 115) with videos related to

Pageof 12
Sort By:
Radiation Oncology (London, England)|January 12, 2011
Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomesDebra E Freeman, Christopher R King
International Journal of Radiation Oncology, Biology, Physics|September 24, 2002
Yes, the alpha/beta ratio for prostate cancer is low or "methinks the lady doth protest too much...about a low alpha/beta that is"Christopher R King, Jack F Fowler
British Journal of Anaesthesia|April 25, 2026
Machine learning models in anaesthesiology: bridging the gap from model training to implementationChristopher R King, Bradley A Fritz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
To treat pelvic nodes or not: could the greater testicular scatter dose from whole pelvic fields confound results of prostate cancer trials?Christopher R King, Daniel S Kapp
Seminars in Radiation Oncology|June 5, 2017
Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate CancerAmar U Kishan, Christopher R King
International Journal of Radiation Oncology, Biology, Physics|February 1, 2008
Radiotherapy after prostatectomy: is the evidence for dose escalation out there?Christopher R King, Daniel S Kapp
Applied Clinical Informatics|February 24, 2021
Ascertaining Design Requirements for Postoperative Care Transition InterventionsJoanna Abraham, Christopher R King, Alicia Meng
Urologic Oncology|September 19, 2008
Prognostic significance of prostate cancer originating from the transition zoneChristopher R King, Michelle Ferrari, James D Brooks
International Journal of Radiation Oncology, Biology, Physics|June 8, 2017
In Reply to ScottNarek Shaverdian, Michael L Steinberg, Christopher R King
Physics in Medicine and Biology|January 10, 2008
A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD)Gary Luxton, Paul J Keall, Christopher R King
Pageof 12

Showing results (11-20 of 115) with videos related to

Sort By:
Pageof 12
Radiation Oncology (London, England)|January 12, 2011
Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomesDebra E Freeman, Christopher R King
International Journal of Radiation Oncology, Biology, Physics|September 24, 2002
Yes, the alpha/beta ratio for prostate cancer is low or "methinks the lady doth protest too much...about a low alpha/beta that is"Christopher R King, Jack F Fowler
British Journal of Anaesthesia|April 25, 2026
Machine learning models in anaesthesiology: bridging the gap from model training to implementationChristopher R King, Bradley A Fritz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
To treat pelvic nodes or not: could the greater testicular scatter dose from whole pelvic fields confound results of prostate cancer trials?Christopher R King, Daniel S Kapp
Seminars in Radiation Oncology|June 5, 2017
Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate CancerAmar U Kishan, Christopher R King
International Journal of Radiation Oncology, Biology, Physics|February 1, 2008
Radiotherapy after prostatectomy: is the evidence for dose escalation out there?Christopher R King, Daniel S Kapp
Applied Clinical Informatics|February 24, 2021
Ascertaining Design Requirements for Postoperative Care Transition InterventionsJoanna Abraham, Christopher R King, Alicia Meng
Urologic Oncology|September 19, 2008
Prognostic significance of prostate cancer originating from the transition zoneChristopher R King, Michelle Ferrari, James D Brooks
International Journal of Radiation Oncology, Biology, Physics|June 8, 2017
In Reply to ScottNarek Shaverdian, Michael L Steinberg, Christopher R King
Physics in Medicine and Biology|January 10, 2008
A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD)Gary Luxton, Paul J Keall, Christopher R King
Pageof 12